PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis

PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis

Background: Few studies have compared the use of different biologics in a real-life setting in plaque psoriasis patients. Objective: To compare the efficacy of biologics in psoriasis/psoriatic arthritis patients. Methods: Patients treated with adalimumab, etanercept and ustekinumab for at least 16 w...

Full description

Bibliographic Details
Main Authors: Carlo Giovanni Carrera, Paolo Dapavo, Piergiorgio Malagoli, Luigi Naldi, Luisa Arancio, Francesca Gaiani, Colin Gerard Egan, Marco Di Mercurio, Angelo Cattaneo
Format: Article
Language:English
Published: Taylor & Francis Group 2018-07-01
Series:Journal of Dermatological Treatment
Subjects:
psoriasis
psoriatic arthritis
biological drugs
adalimumab
etanercept
ustekinumab
Online Access:http://dx.doi.org/10.1080/09546634.2017.1395805

Similar Items

Similar Items